Symbiotec Pharmalab
Symbiotec Pharmalab Share Price Chart
Symbiotec Pharmalab last traded at ₹1,098.20 (2026-10-13). Over the past month the stock moved -3.7%. Its closing range over 52 weeks is ₹1,004.25 – ₹1,199.30, with the latest close 8.4% below the high.
Closing prices up to 2026-10-13.
Fundamentals
Quarterly Results
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2025 | 203.00 | 58.00 | 29.00 | 30.00 | 46.99 |
Annual Financials
In the latest year (Mar 2026), Symbiotec Pharmalab reported sales of ₹869.00 crore (+15.6%) and net profit of ₹110.00 crore (+13.4%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 869.00 | 239.00 | 27.00 | 110.00 | 17.51 |
| Mar 2025 | 752.00 | 203.00 | 27.00 | 97.00 | 151.98 |
| Mar 2024 | 716.00 | 172.00 | 24.00 | 100.00 | 91.49 |
| Mar 2023 | 567.00 | 70.00 | 12.00 | 23.00 | 21.48 |
| Mar 2022 | 682.00 | 131.00 | 19.00 | 78.00 | 70.89 |
| Mar 2021 | 633.00 | 195.00 | 31.00 | 123.00 | 112.72 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales growth | +7.7% | -16.9% | +26.3% | +5.0% | +15.6% |
| Operating profit growth | -32.8% | -46.6% | +145.7% | +18.0% | +17.7% |
| Net profit growth | -36.6% | -70.5% | +334.8% | -3.0% | +13.4% |
| EPS growth | -37.1% | -69.7% | +325.9% | +66.1% | -88.5% |
| OPM % | 19.0% | 12.0% | 24.0% | 27.0% | 27.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Symbiotec Pharmalab.
Get Free AI Stock Analysis FREE →Latest News
-
Symbiotec Pharmalab receives EIR from USFDA for Pithampur facility with VAI status
-
Symbiotec Pharmalab receives EIR report for Pithampur SEZ unit - Business Standard
-
Symbiotec Pharmalab surges after Pithampur facility gets EIR from US FDA - Business Standard
-
Symbiotec Pharmalab consolidated net profit declines 53.01% in the June 2026 quarter - Business Standard
-
Symbiotec Pharmalab consolidated net profit declines 53.01% in the June 2026 quarter - Business Standard
-
Symbiotec Pharmalab posts nearly 53% YoY fall in Q1 PAT - Business Standard
Frequently Asked Questions
What is the share price of Symbiotec Pharmalab today?
Symbiotec Pharmalab shares were last quoted at ₹1,098.20 (+1.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Symbiotec Pharmalab?
Symbiotec Pharmalab has a price-to-earnings (P/E) ratio of 0.00 and a price-to-book (P/B) ratio of 5.62. The industry P/E is 53.33.
What is the 52-week high and low of Symbiotec Pharmalab?
The 52-week high of Symbiotec Pharmalab is ₹1,193.90 and the 52-week low is ₹933.80.
What is the market cap of Symbiotec Pharmalab?
The market capitalisation of Symbiotec Pharmalab is about ₹6,452.92 crore.
What is the promoter holding in Symbiotec Pharmalab?
Promoters hold about 33.28% of Symbiotec Pharmalab.
Which sector does Symbiotec Pharmalab belong to?
Symbiotec Pharmalab belongs to the Pharmaceuticals & Drugs sector.